Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Aug;41(4):98-99.
doi: 10.18773/austprescr.2018.032. Epub 2018 Aug 1.

Fast-tracking of new drugs: getting the balance right

Paul Kubler  1
Affiliations
Editorial

Fast-tracking of new drugs: getting the balance right

Paul Kubler. Aust Prescr. 2018 Aug.
No abstract available

Keywords: drug regulation; product approval.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Paul Kubler received sponsorship from Bristol-Myers Squibb to attend the 2017 EULAR Annual European Congress of Rheumatology and has acted as a consultant to Abbvie, Eli Lilly and Reckitt Benckhiser.

References

    1. Sansom L, Delaat W, Horvath J. Review of medicines and medical devices regulation: report on the regulatory framework for medicines and medical devices. Canberra: Department of Health; 2015. http://www.health.gov.au/ internet/main/publishing.nsf/content/expert-re... [cited 2018 Jul 1]
    1. Therapeutic Goods Administration. Consultation: expedited pathways for prescription medicines. Eligibility criteria and designation process. Version 1.0, Oct 2016. Canberra: Therapeutic Goods Administration; 2016. https://www.tga.gov.au/consultation/consultation-expedited-pathways-pres... [cited 2018 Jul 1]
    1. Therapeutic Goods Administration. Priority review registration process: for priority review designated prescription medicines. Version 1.1, July 2017. Canberra: Therapeutic Goods Administration; 2017. https://www.tga.gov.au/publication/priority-review-registration-process [cited 2018 Jul 1]
    1. Center for Drug Evaluation and Research. Advancing health through innovation: 2017 new drug therapy approvals. Silver Spring (MD): US Food and Drug Administration; 2018. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DrugInnovation/ucm5... [cited 2018 Jul 1]
    1. Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 2017;359:j4530. 10.1136/bmj.j4530 - DOI - PMC - PubMed

Publication types

LinkOut - more resources